• Arena Announces First Subject Dosed Etrasimod Trial for Ulcerative Colitis americanpharmaceuticalreview
    September 23, 2020
    Arena Pharmaceuticals announced the first subject has been dosed in the ELEVATE UC 12 global Phase 3 trial evaluating etrasimod, an investigational, next-generation, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator ...
PharmaSources Customer Service